We have demonstrated previously the oncolytic effects of a systemically delivered, replicating
vaccinia virus. To enhance the tumor specificity of this vector, we have developed a …

Oncolytic viruses (OVs) are selected or designed to eliminate malignancies by direct infection
and lysis of cancer cells. In contrast to this concept of direct tumor lysis by viral infection, …

Efforts to selectively target and disrupt established tumor vasculature have largely failed to
date. We hypothesized that a vaccinia virus engineered to target cells with activation of the ras…

Metastatic cancer remains an incurable disease in the majority of cases and thus novel
treatment strategies such as oncolytic virotherapy are rapidly advancing toward clinical use. In …

To expand our current array of safe and potent oncolytic viruses, we screened a variety of
wild-type (WT) rhabdoviruses against a panel of tumor cell lines. Our screen identified a …

Purpose: The oncolytic effects of a systemically delivered, replicating, double-deleted
vaccinia virus has been previously shown for the treatment of many cancers, including colon, …

Oncolytic viral therapy utilizes a tumor-selective replicating virus which preferentially infects
and destroys cancer cells and triggers antitumor immunity. The Western Reserve strain of …

A major barrier to all oncolytic viruses (OVs) in clinical development is cellular innate
immunity, which is variably active in a spectrum of human malignancies. To overcome the …

Oncolytic viruses designed to attack malignant cells can in addition infect and destroy tumor
vascular endothelial cells. We show here that this expanded tropism of oncolytic vaccinia …

Oncolytic viruses (OVs) have shown promising clinical activity when administered by direct
intratumoral injection. However, natural barriers in the blood, including antibodies and …